ADC Therapeutics SA, a leader in the field of antibody drug conjugates, has announced a new compensation agreement for a recently hired employee. The company has granted options to purchase 17,000 common shares as an inducement for employment, approved by the Compensation Committee under the Inducement Plan. These options will vest 25% after one year, with the remainder vesting monthly over the following three years, contingent on continued employment. This move aligns with ADC Therapeutics' commitment to rewarding its workforce through strategic grants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.